Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 819053, 10 pages
http://dx.doi.org/10.1155/2014/819053
Research Article

Scropolioside B Inhibits IL-1β and Cytokines Expression through NF-κB and Inflammasome NLRP3 Pathways

1Murad Research Institute for Modernized Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received 9 June 2014; Revised 6 August 2014; Accepted 20 August 2014; Published 16 October 2014

Academic Editor: Antonio Macciò

Copyright © 2014 Tiantian Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Pawelec, D. Goldeck, and E. Derhovanessian, “Inflammation, ageing and chronic disease,” Current Opinion in Immunology, vol. 29, no. 1, pp. 23–28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. L. M. Coussens, L. Zitvogel, and A. K. Palucka, “Neutralizing tumor-promoting chronic inflammation: a magic bullet?” Science, vol. 339, no. 6117, pp. 286–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. G. E. McKellar, D. W. McCarey, N. Sattar, and I. B. McInnes, “Role for TNF in atherosclerosis? Lessons from autoimmune disease,” Nature Reviews, vol. 6, no. 6, pp. 410–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. V. H. Perry and J. Teeling, “Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration,” Seminars in Immunopathology, vol. 35, no. 5, pp. 601–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Schmitz, A. Weber, T. Roxlau, M. Gaestel, and M. Kracht, “Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1813, no. 12, pp. 2165–2175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Strowig, J. Henao-Mejia, E. Elinav, and R. Flavell, “Inflammasomes in health and disease,” Nature, vol. 481, no. 7381, pp. 278–286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Duewell, H. Kono, K. J. Rayner et al., “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,” Nature, vol. 464, pp. 1357–1361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Schroder, R. Zhou, and J. Tschopp, “The NLRP3 inflammasome: a sensor for metabolic danger?” Science, vol. 327, no. 5963, pp. 296–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Masters, A. Dunne, S. L. Subramanian et al., “Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes,” Nature Immunology, vol. 11, no. 10, pp. 897–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Petrasek, S. Bala, T. Csak et al., “IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice,” Journal of Clinical Investigation, vol. 122, no. 10, pp. 3476–3489, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Dupaul-Chicoine, G. Yeretssian, K. Doiron et al., “Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases,” Immunity, vol. 32, no. 3, pp. 367–378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. I. Sidiropoulos, G. Goulielmos, G. K. Voloudakis, E. Petraki, and D. T. Boumpas, “Inflammasomes and rheumatic diseases: evolving concepts,” Annals of the Rheumatic Diseases, vol. 67, no. 10, pp. 1382–1389, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Latz, T. S. Xiao, and A. Stutz, “Activation and regulation of the inflammasomes,” Nature Reviews Immunology, vol. 13, no. 6, pp. 397–411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. L.-Q. Zhang and Y.-M. Li, “Advances in studies on chemical constituents in plants of Scrophularia L. and their pharmacological effects in recent ten years,” Chinese Traditional and Herbal Drugs, vol. 42, no. 11, pp. 2360–2368, 2011 (Chinese). View at Google Scholar · View at Scopus
  16. A. Viljoen, N. Mncwangi, and I. Vermaak, “Anti-inflammatory iridoids of botanical origin,” Current Medicinal Chemistry, vol. 19, no. 14, pp. 2104–2127, 2012. View at Google Scholar · View at Scopus
  17. R. Tundis, M. R. Loizzo, F. Menichini, and G. A. Statti, “Biological and pharmacological activities of iridoids: recent developments,” Mini-Reviews in Medicinal Chemistry, vol. 8, no. 4, pp. 399–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Bas, M. C. Recio, S. Máñez et al., “New insight into the inhibition of the inflammatory response to experimental delayed-type hypersensitivity reactions in mice by scropolioside A,” European Journal of Pharmacology, vol. 555, no. 2-3, pp. 199–210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Ahmed, A. J. Al-Rehaily, T. A. Al-Howiriny, K. A. El-Sayed, and M. S. Ahmad, “Scropolioside-D2 and harpagoside-B: two new iridoid glycosides from Scrophularia deserti and their antidiabetic and antiinflammatory activity,” Biological and Pharmaceutical Bulletin, vol. 26, no. 4, pp. 462–467, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Stavri, K. T. Mathew, and S. Gibbons, “Antimicrobial constituents of Scrophularia deserti,” Phytochemistry, vol. 67, no. 14, pp. 1530–1533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. P. B. Benito, A. M. D. Lanza, A. M. S. Sen et al., “Effects of some iridoids from plant origin on arachidonic acid metabolism in cellular systems,” Planta Medica, vol. 66, no. 4, pp. 324–328, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Wang, L. Sun, J. Tan, J. Xu, F. Guo, and Y. Li, “Two new glycosidated coumaramides from Clerodendron cyrtophyllum,” Fitoterapia, vol. 83, no. 8, pp. 1494–1499, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zhang, L. Feng, Q. Jia et al., “Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro,” Bioorganic and Medicinal Chemistry, vol. 19, no. 16, pp. 4882–4886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. K. S. Park, B. H. Kim, and I.-M. Chang, “Inhibitory potencies of several iridoids on cyclooxygenase-1, cyclooxygnase-2 enzymes activities, tumor necrosis factor-α and nitric oxide production In Vitro,” Evidence-based Complementary and Alternative Medicine, vol. 7, no. 1, pp. 41–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. H.-J. Choi, H.-J. Jang, T.-W. Chung et al., “Catalpol suppresses advanced glycation end-products-induced inflammatory responses through inhibition of reactive oxygen species in human monocytic THP-1 cells,” Fitoterapia, vol. 86, no. 1, pp. 19–28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C. A. Nold-Petry, M. F. Nold, J. A. Zepp, S.-H. Kim, N. F. Voelkel, and C. A. Dinarello, “IL-32-dependent effects of IL-1β on endothelial cell functions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3883–3888, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. V. A. K. Rathinam, S. K. Vanaja, and K. A. Fitzgerald, “Regulation of inflammasome signaling,” Nature Immunology, vol. 13, no. 4, pp. 333–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S. S. Iyer, Q. He, J. R. Janczy et al., “Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation,” Immunity, vol. 39, no. 2, pp. 311–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Dinarello, “A clinical perspective of IL-1β as the gatekeeper of inflammation,” European Journal of Immunology, vol. 41, no. 5, pp. 1203–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. L. A. B. Joosten, M. G. Netea, S.-H. Kim et al., “IL-32, a proinflammatory cytokine in rheumatoid arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3298–3303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Heinhuis, M. I. Koenders, F. A. Van De Loo, M. G. Netea, W. B. Van Den Berg, and L. A. B. Joosten, “Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4962–4967, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. Y.-G. Kim, C.-K. Lee, S.-H. Kim, W.-S. Cho, S. H. Mun, and B. Yoo, “Interleukin-32γ enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes Via Erk1/2 activation,” Journal of Clinical Immunology, vol. 30, no. 2, pp. 260–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. A. R. Moschen, T. Fritz, A. D. Clouston et al., “Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis,” Hepatology, vol. 53, no. 6, pp. 1819–1829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. Q. Xu, X. Pan, X. Shu et al., “Increased interleukin-32 expression in chronic hepatitis B virus-infected liver,” Journal of Infection, vol. 65, no. 4, pp. 336–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. S.-H. Kim, S.-Y. Han, T. Azam, D.-Y. Yoon, and C. A. Dinarello, “Interleukin-32: a cytokine and inducer of TNFα,” Immunity, vol. 22, no. 1, pp. 131–142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Nold-Petry, I. Rudloff, Y. Baumer et al., “IL-32 promotes angiogenesis,” Journal of Immunology, vol. 192, no. 2, pp. 589–602, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Kobayashi, J. Huang, F. Ye, Y. Shyr, T. S. Blackwell, and P. C. Lin, “Interleukin-32β propagates vascular inflammation and exacerbates sepsis in a mouse model,” PLoS ONE, vol. 5, no. 3, Article ID e9458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Heinhuis, C. D. Popa, B. L. J. H. van Tits et al., “Towards a role of interleukin-32 in atherosclerosis,” Cytokine, vol. 64, no. 1, pp. 433–440, 2013. View at Publisher · View at Google Scholar · View at Scopus